Visual outcomes
Of the 516 patients in the overall FAS, 435 had a BCVA evaluation at baseline and month 12 and could be included in the analysis of the primary outcome. The overall mean change in BCVA (baseline, 57.2 ± 18.9) was 5.1 ± 15.7 letters at month 12 (For all cohorts, the BCVA gains peaked after 3 months of treatment but returned to near-baseline levels by the end of the 48-month study period (Fig. Mean change from baseline in BCVA for the FAS (before switch) and 3 IVT-AFL treatment cohorts. *There were no significant differences in the change in BCVA from baseline to month 48 between patients in the FAS who received < 7 or ≥ 7 injections in the first 12 months of treatment (data not shown). Similarly, there were no clear trends when considering the number of injections received (0–3, 4–6, 7–9, and > 9) during the first 12 months and the gain or loss of letters (Online Resource Of 263 patients in the FAS with a BCVA assessment at month 48, between baseline and month 48, 65 patients (24.7%) gained ≥ 15 letters, 88 (33.5%) gained ≥ 10 letters, 122 (46.4%) gained ≥ 5 letters, and 28 (10.6%) gained 0–4 letters, whereas 50 patients (19.0%) lost ≥ 15 letters. The proportion of these patients with BCVA < 50 letters was 24.3% (64/263) at baseline and 27.4% (72/263) at month 48. In the overall FAS, the proportion of patients with a BCVA ≥ 70 letters increased significantly (